Organovo and the implementation of 3D printers in BioTechnology

Scientists, scientifically curious investors and Sci-Fi fanatics keep their eyes wide open on Organovo, waiting patiently for the next breakthrough of the company. Organovo developed the first commercial 3D bio-printing platform, and in 2013 the company presented data describing key features of a 3D human liver model, which is in development since then.

The idea is to use the technology to create artificial 3D printed liver cells that will form a liver tissue for biotechnology companies to use in their clinical trials, saving them time and millions of dollars. The challenge is to make the printed tissue react to chemicals and toxins similar to how a real liver would. This challenge, it seems, is now behind us.

At the 3D Cell Culture 2014 conference held in Germany on Thursday (June 26th), a representative of Roche, the Swiss based global pharmaceuticalsand diagnostics company, presented results gathered from a study conducted on Organovo’s 3D printed liver cells. Dr. Adrian Roth, head of mechanistic safety for Roche emphasized two major conclusions:

“Organovo’s 3D Liver system was able to distinguish a toxic drug known to cause drug induced liver injury (DILI) from a close chemical analogue that is known to be non-toxic.

The toxicity of the toxic compound was detected at physiologically relevant doses, an important observation not previously reported with the same compounds in other model liver systems.” … (Read more)

Source: FinancialBuzz.com